Cancer Patients More Likely to Die From Early Omicron Variants of SARS-CoV-2
Cancer patients were more likely to die from the BA.1 and BA.2 omicron variants of SARS-CoV-2 than from wild-type SARS-CoV-2, data suggest.
Cancer patients were more likely to die from the BA.1 and BA.2 omicron variants of SARS-CoV-2 than from wild-type SARS-CoV-2, data suggest.
The burden of administrative tasks required to pay for cancer care is associated with nonadherence to care, a new study suggests.
Cancer death rates have declined in the United States in recent years, but the declines are greater in urban than in rural areas, data suggest.
Deaths in patients with COVID-19 and cancer made up 81% of excess deaths among cancer patients during the first 2 years of the pandemic.
Cancer patients may be particularly susceptible to transportation-related disruptions in care.
The main cause of the cancer drug shortage, experts agree, is the underlying weakness of the generic drug industry.
Malnutrition may affect 30% to 85% of cancer patients, and it may account for 10% to 20% of deaths in these patients.
Health insurers and medical providers are battling over who should supply high-cost infusion drugs for patients.
A novel blood test can detect cancers that currently have no standard screening procedures, a study suggests.